CollPlant

115 articles about CollPlant

• CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

  6/29/2022

  CollPlant today announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market.

• CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results

  5/26/2022

  CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the first quarter ended March 31, 2022.

• CollPlant To Present at the Aesthetics Innovation Summit 2022

  4/13/2022

  CollPlant today announced that Dr. Jasmine Seror, CollPlant's Head of Aesthetic Medicine and Exploratory Products, will deliver a presentation at the Aesthetics Innovation Summit 2022, to be held in San Diego, California, on Wednesday, April 20, 2022.  

• CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results

  3/24/2022

  - Record revenues in 2021 of $15.6 million versus $6.1 million in 2020 - Continued progress of strategic agreement with AbbVie to develop dermal and soft tissue filler products using CollPlant's rhCollagen - Company to advance 3D bioprinted regenerative breast implant program with launch of large animal study expected in Q2 - Strong balance sheet with $43.3 million cash position, as of December 31, 2021   [24

• CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal

  12/2/2021

  CollPlant Biotechnologies today announced the publication of an article in the Plastic and Reconstructive Surgery journal.

• CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results

  11/18/2021

  CollPlant Biotechnologies today announced business updates and financial results for the third quarter ended September 30, 2021.

• CollPlant to Present at Dawson James Small Cap Growth Conference on October 21st

  10/14/2021

  CollPlant Biotechnologies today announced that the Company's Deputy CEO & Chief Financial Officer Eran Rotem , will present a company overview at the Dawson James 6th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida.

• CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs

  10/11/2021

  CollPlant Biotechnologies today announced that its recombinant human collagen (rhCollagen)-based bioink was used successfully by researchers from Israel's Technion Institute of Technology to create a 3D bioprinted implantable tissue containing a network of blood vessels capable of supplying blood to the implanted tissue.

• CollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021

  9/30/2021

  CollPlant Biotechnologies has been invited to present at the Fall Harvest – Best Ideas from the Buy-Side conference, which is being held virtually on October 5th – 8th

• CollPlant To Present at the H.C. Wainwright Annual Global Investment Conference in September 2021

  9/7/2021

  CollPlant announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, will provide an overview of the company at the H.C. Wainwright 23rd Annual Global Investment Conference which will be held virtually on September 13-15, 2021.

• CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results

  8/19/2021

  CollPlant today announced financial results for the second quarter ended June 30, 2021 and provided an update on the Company's business developments.

• CollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs

  6/4/2021

  CollPlant, a regenerative and aesthetic medicine company, announced the uplisting of its ordinary shares to the Nasdaq Global Select Market® effective at the open of market, Friday, June 4, 2021.

• CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million

  5/27/2021

  CollPlant, a regenerative and aesthetic medicine company, announced financial results for the first quarter ended March 31, 2021 and provided an update on the Company's business developments.

• CollPlant Announces Uplisting to the Nasdaq Global Market® and Transition to Trading of Ordinary Shares Instead of ADSs

  5/25/2021

  CollPlant, a regenerative and aesthetic medicine company, announced that its ordinary shares have been approved for trading on the Nasdaq Global Market® under the Company's current ticker symbol "CLGN" and will begin trading at the open of market on June 4, 2021.

• CollPlant Appoints Additive Manufacturing Executive, Hugh Evans to Its Board of Directors

  3/29/2021

  CollPlant (NASDAQ: CLGN),   a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members.

• CollPlant To Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  CollPlant (NASDAQ: CLGN),   a regenerative and aesthetics medicine company, today announced that Mr. Yehiel Tal , Chief Executive Officer of CollPlant, will provide an overview of the company at the H.C. Wainwright Global Life Sciences Conference which will be held virtually on March 9-10, 2021 .

• CollPlant Issues Letter to Shareholders - Feb 18, 2021

  2/18/2021

  Expansion of collaboration with United Therapeutics to cover a second lifesaving organ, human kidneys, in addition to lungs

• CollPlant Biotechnologies Reports Third Quarter (Q3) 2020 Financial Results and Provides Business Update

  12/1/2020

  - Expanded collaboration agreement with United Therapeutics which exercised its option for 3D bioprinted kidney transplants and $3 million payment to CollPlant - Increased revenues from 3D Bioprinting and Medical Aesthetics Business Collaborations

• CollPlant Announces Early Development Program of Antiviral Agent for Potential Treatment of COVID-19 Patients

  11/10/2020

  Pre-clinical results show significant inhibition of avian coronavirus infectivity when treated with CollPlant's novel approach

• CollPlant Receives Substantial First Order for its Vergenix™ Flowable Gel Product in Ukraine

  10/26/2020

  CollPlant a regenerative and aesthetic medicine company, announced that it has received a substantial first order totaling hundreds of thousands of U.S. dollars for its Vergenix™ Flowable Gel product in Ukraine from CollPlant's new distribution partner, a Russia-based biopharmaceutical company.